{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 60,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 36,
  "notes": "Clinical trial baseline data table.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/14",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.085,
        "w": 0.954,
        "x": 0.023,
        "y": 0.865
      },
      "kind": "source-note",
      "text": "*worst score over past week **includes clindamycin and chlorhexidine ªincludes 2 pts with very severe disease; 1 patient with very severe disease received infliximab and bimekizumab (and adalimumab) AD=Atopic Dermatitis; AN=Abscess and Inflammatory Nodule Count; EASI=Eczema Area and Severity Index; HS=hidradenitis suppurativa; Min=minimum; Max=maximum; Pain-NRS=Skin Pain Numerical Rating Score; Pruritus-NRS=Peak Pruritus Numerical Rating Score; PGA=Physicians Global Assessment; IGA=Investigator Global Assessment",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "611099b2-9ab9-4240-8f4e-efd89e09b821",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.735,
        "w": 0.954,
        "x": 0.023,
        "y": 0.165
      },
      "kind": "table",
      "text": "Table comparing HS and AD patient characteristics across severity, disease extent, and prior therapy.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9614d43c-690b-408b-92cc-919caf2b200b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.424,
        "x": 0.288,
        "y": 0.045
      },
      "kind": "title",
      "text": "Baseline Disease Characteristics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49fe710a-fb19-4d8c-b934-8a9af880764e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 9,
      "beatId": "285a4680-d771-4271-8dc2-ebdc0e60f9a4",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The slides on Kymera's pipeline and clinical data create desire for the solution",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}